Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Clin Lymphoma Myeloma Leuk ; 20(7): e375-e381, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32295735

RESUMEN

BACKGROUND: The programmed death receptor (PD-1) and ligand (PD-L1) pathway act by suppressing the antitumor response in chronic Hodgkin lymphoma (cHL). In this study, we aimed to investigate the effect of PD-1, PD-L1, and Epstein-Barr virus (EBV) positivity on prognosis at the initial diagnosis of cHL. MATERIAL AND METHODS: Thirty-six patients with cHL were retrospectively analyzed. PD-L1 staining was performed for RS cells and tumor microenvironment in the biopsy materials of cases. The presence of EBV was investigated by EBER (EBV-encoded RNA) method in tumor cell. P < .05 was accepted as significant. RESULTS: The presence of advanced-stage disease, B symptoms, intermediate or high-risk international prognostic index (IPS), and extranodal involvement were found to be related to both PD-L1 positivity and EBV positivity in RS cells. PD-L1 positivity in RS cells was also associated with EBV positivity. There were 6 (16.7%) triple-positive (EBV+, RS-PD-L1+, mic-PD-1+) patients. All of these patients had advanced-stage disease, B symptoms at the time of diagnosis, and intermediate-high IPS score, and 4 of 6 patients had extranodal involvement. This group also had significantly shortened overall survival compared with others (38.4 months vs. 67.9 months P = .024). CONCLUSION: Our data suggest that there is correlation between PD-L1 positivity and EBV positivity in tumor RS cells that are also associated with extranodal involvement, intermediate and high IPS score, presence of B symptoms, and advanced-stage disease. In addition, we identified a group of triple-positive (EBV+, RS-PD-L1+, mic-PD-1+) cHL patients who have a very high-risk disease.


Asunto(s)
Antígeno B7-H1/metabolismo , Infecciones por Virus de Epstein-Barr/virología , Enfermedad de Hodgkin/genética , Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Receptor de Muerte Celular Programada 1/metabolismo , Adulto , Anciano , Femenino , Enfermedad de Hodgkin/patología , Humanos , Inhibidores de Puntos de Control Inmunológico/farmacología , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Adulto Joven
2.
Turk Patoloji Derg ; 34(3): 199-206, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29708579

RESUMEN

OBJECTIVE: Although classical Hodgkin lymphoma (cHL) has a relatively good prognosis, it also entails different treatment responses and involves patients who have different clinical courses. Our aim was to investigate c-Myc, Bcl-2 and EBV biomarkers in cHL and their relationship with the IPS score. MATERIAL AND METHOD: c-Myc and Bcl-2 immunohistochemical staining with EBER in situ hybridization (EBER-ISH) was applied to the paraffin sections of 94 cases diagnosed as cHL. These cases were classified into two groups as low and high clinical symptoms according to the International Prognostic Scores (IPS). RESULTS: Positive results were obtained in 83 (88.3%) cases with c-Myc and 39 (43.5%) cases with Bcl-2 while EBER-ISH was found positive in 42 (44.7%) cases. No difference was found between the groups of low/high IP scores with respect to the positive or negative results of EBER-ISH, Bcl-2 and c-Myc. When Bcl-2 and c-Myc positive cases were grouped together and compared to the IP scores of the remaining cHL cases, again no difference was seen. Extranodal involvement and bone marrow involvement was observed in 25 (26.5%) and 9 (9.5%) cases, respectively. Similarly, no statistically significant differences was found between these groups according to their positivity with EBER-ISH, Bcl-2 and c-Myc. CONCLUSION: We could not find any relationship between Bcl-2, c-Myc and EBER-ISH positivity and the low/high IPS groups in cHL. New studies with larger series are needed in which more precise cut-off values are used and clinically and biologically heterogeneous groups of cHL patients are determined more clearly.


Asunto(s)
Biomarcadores de Tumor/análisis , Infecciones por Virus de Epstein-Barr/epidemiología , Enfermedad de Hodgkin/clasificación , Proteínas Proto-Oncogénicas c-bcl-2/biosíntesis , Proteínas Proto-Oncogénicas c-myc/biosíntesis , Adolescente , Adulto , Anciano , Femenino , Enfermedad de Hodgkin/mortalidad , Enfermedad de Hodgkin/patología , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Proteínas Proto-Oncogénicas c-bcl-2/análisis , Proteínas Proto-Oncogénicas c-myc/análisis , Factores de Riesgo , Adulto Joven
3.
Int J Surg Case Rep ; 28: 15-17, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27662215

RESUMEN

INTRODUCTION: Adrenal haemorrhage is a relatively rare condition. If there is not a specific ethology describing adrenal hematoma, then, this is termed as 'idiopathic adrenal hematoma'. PRESENTATION OF CASE: We presented a case of idiopathic adrenal hematoma in this study. A 62-year-old woman was referred to our hospital for evaluation of a 40mm mass in the left upper abdominal cavity. The histopathological findings of the surgical specimen revealed a hematoma with normal adrenal tissue. DISCUSSION: The incidence of adrenal haemorrhage was found to be 1.1% regarding autopsy results. The Adrenal gland is highly vascular and vulnerable to haemorrhage. Before a surgical operation, it is difficult to diagnose idiopathic adrenal hematomas. CONCLUSION: An adrenal hematoma should be kept in mind when adrenal masses assessing.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...